Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Baldeon
 
SRCTN85216856
RCTconvalescent plasma treatmentplaceboCOVID 19 hospitalizedsome concern
63/95 inconclusive
    ITAC
     
    NCT04546581
    RCTneutralizing antibodyplaceboCOVID 19 hospitalizedsome concern
    301/292 inconclusive
    • inconclusive 6 % increase in clinical improvement,clinical improvement (7-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
    trial did not meet its endpoints (press release)
    Bennett-Guerrero
     
    NCT04344535
    RCTconvalescent plasma treatmentplaceboCOVID 19 hospitalizedsome concern
    59/15 inconclusive
      CCAP-2
       
      NCT04345289
      RCTconvalescent plasma treatmentplaceboCOVID 19 hospitalizedlow
      98/46 inconclusive
        CONTAIN COVID-19
         
        NCT04364737
        RCTconvalescent plasma treatmentplaceboCOVID 19 hospitalizedsome concern
        468/473 inconclusive
        • inconclusive 6 % decrease in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
        NCT04442191
         
        NCT04442191
        RCTconvalescent plasma treatmentplaceboCOVID 19 hospitalizedlow
        8/6 inconclusive

          COVID-19 mild to moderate meta-analysis

          Libster
           
          NCT04479163
          RCTconvalescent plasma treatmentplaceboCOVID-19 mild to moderatelow
          80/80 conclusif
          • demonstrated 48 % decrease in clinical deterioration (PE) with a high degree of certainty due to low risk of bias

          COVID-19 severe or critically meta-analysis

          O’Donnell
           
          NCT04359810
          RCTconvalescent plasma treatmentplaceboCOVID-19 severe or criticallylow
          150/73 inconclusive
          • inconclusive 38 % increase in clinical improvement (28-day) (PE) with a high degree of certainty due to low risk of bias
          PlasmAr
           
          NCT04344535
          RCTconvalescent plasma treatmentplaceboCOVID-19 severe or criticallylow
          228/106 inconclusive
          • inconclusive 19 % decrease in clinical improvement (PE) with a high degree of certainty due to low risk of bias
          5 studies excluded by filtering options (5 RCT / 0 OBS)

          PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
          Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).